- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04550312
The Impact of Lifestyle Changes on Non-COVID Deaths
The Impact of Lifestyle Alteration by Strict Prevention Measures on Non-COVID Deaths in the Region With Low COVID-19 Transmission Rate
Study Overview
Status
Conditions
Detailed Description
Background The increase of all-cause mortality in the areas with high COVID-19 transmission rate due to COVID-19 deaths and the collateral damage to other healthcare problems is well known. However, the COVID-19 mortality is very low in the regions with low transmission rate and sufficient medical resources. In such regions, strict prevention measures were taken and these would alter the people's lifestyle and hygienic habits and further impact on non-COVID-19 deaths. Yet, there has no thorough investigation in this aspect.
Methods The number of registered deaths among 8.8 million permanent residents with specific causes from January 2018 to June 2020 were sourced from the Xuzhou Center for Disease Control and Prevention, Jiangsu Province, China. Death rates were calculated and compared by weeks, months, and years with a focus on the period of COVID-19 pandemic from Jan 24 to March 27, 2020. Numeric values of all-cause death and the death rates of non-COVID diseases were compared in time series at different time scales.
Study Type
Enrollment (Anticipated)
Contacts and Locations
Study Locations
-
-
Jiangsu
-
Xuzhou, Jiangsu, China, 221000
- Recruiting
- Xuzhou Medical University Affiliated Hospital
-
Contact:
- Ming Chu, PHD
-
Sub-Investigator:
- Chenzong Li, PHD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Child
- Adult
- Older Adult
Accepts Healthy Volunteers
Genders Eligible for Study
Sampling Method
Study Population
Description
Inclusion Criteria:
- All cases of death reported to the Xuzhou CDC during the study period
Exclusion Criteria:
- no
Study Plan
How is the study designed?
Design Details
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Numeric values of all-cause death and the death rates of non-COVID diseases
Time Frame: from January 2018 to June 2020
|
from January 2018 to June 2020
|
Collaborators and Investigators
Investigators
- Principal Investigator: minglong chen, PHD, Xuzhou Medical University Affiliated Hospital
Study record dates
Study Major Dates
Study Start (Anticipated)
Primary Completion (Anticipated)
Study Completion (Anticipated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- XYFY2020-KL142-01
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lifestyle Alteration
-
BioMed Valley Discoveries, IncTerminatedAdvanced Solid Tumor | MAP2K1 Gene Mutation | BRAF Gene Mutation | MEK Mutation | BRAF Gene Alteration | MEK Alteration | MAP2K1 Gene Alteration | MAP2K2 Gene Mutation | MAP2K2 Gene AlterationUnited States
-
Cairo UniversityUnknown
-
Danone Asia Pacific Holdings Pte, Ltd.CompletedImmunologic Activity Alteration
-
Children's Hospital of PhiladelphiaNational Institute of Neurological Disorders and Stroke (NINDS)Completed
-
United States Army Research Institute of Environmental...United States Department of DefenseCompletedDietary Modification | Bone AlterationUnited States
-
National Taiwan University HospitalCompletedAlteration of Cognitive FunctionTaiwan
-
Northumbria UniversityCompletedAlteration of Cognitive FunctionUnited Kingdom
-
University of California, IrvineBeckman Laser Institute University of California Irvine; Unilever R&DCompletedCollagen Fibril AlterationUnited States
-
University of Sao PauloUnknown
-
Ramathibodi HospitalCompletedAlteration of Modified Mallampati Score